Good Move on Bad Drugs
The Ranbaxy Scandal

Resident Fellow
Roger Bate
The U.S. Food and Drug Administration has just banned 30 drugs from India's giant Ranbaxy Laboratories because of quality fears, but the move is long overdue and Ranbaxy continues to supply the developing world with other drugs that are not checked for quality.

The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) later suspended purchases of Ranbaxy drugs too, after buying US$9 million last year, but this has not been matched by the other agencies and countries that supply low-quality drugs to poor countries--supplied in line with World Health Organization (WHO) recommendations.

Deficiencies in HIV anti-retrovirals (ARVs) or in malaria drugs can increase patient resistance to drugs and help the disease mutate into new and virulent forms. Rising resistance in sub-Saharan Africa, Thailand and Cambodia is a time-bomb that will increase deaths from AIDS and will multiply the cost of treatment many times over.

As the contaminated milk horror grows in China, quality control in food and drug manufacturing in the rapidly-developing world is a matter of life and death.

The FDA says its action against Ranbaxy's Paonto Sahib and Dewas plants is "preventive." It has known about problems at Ranbaxy's plants for several years but it "recommends that consumers continue taking their medications manufactured by Ranbaxy," so the ban seems to be a punishment for Ranbaxy refusing to allow an audit rather than any immediate fear about drugs sold in the U.S.: None of those have failed quality tests.

But back in 2005, a whistleblower from Ranbaxy contacted me with evidence of safety-data manipulation, including data on HIV drugs for Africa. We forwarded this to U.S. authorities and the WHO. In June 2006, the FDA warned Ranbaxy that it would "recommend withholding approval" of Paonto Sahib products until deficiencies were corrected. Nearly a year later the company's counsel admitted "that it had not yet addressed all of the FDA's concerns." Early this year, the FDA inspected both suspect plants and found "serious violations."

Then, in July this year, the U.S. Department of Justice said "allegations from reliable sources and supporting documents indicate a pattern of systemic fraudulent conduct." It said Ranbaxy uses active pharmaceutical ingredients (API) "from unapproved sources, blends unapproved API with approved API, and uses less API in its drug than had been approved by the FDA."But since its investigation began in early 2007, the FDA has approved 18 Ranbaxy drugs for the U.S. PEPFAR has bought US$9 million of its HIV drugs (not certified in the U.S.), and distributed more than 1.8 million packages to 15 countries, mainly in Africa.

Part of the reason for FDA inertia may be the stature of Ranbaxy, the largest Indian drug maker, valued at over US$4 billion (although shares fell roughly 10 percent after the FDA announcement), and probably the tenth-largest maker in the world of generics (copies of formerly-patented drugs). The U.S. accounts for 28 percent of its sales.

Ranbaxy says that "except for issues that have already been fully aired" with the U.S. government, it "knows of no evidence to support" the Justice Department case--and no charges have yet been laid.

The Indian Government has called for a swift resolution and the Commerce Department has hinted it will complain, perhaps through the World Trade Organization. But speed is not as important as establishing good precedent.

The FDA is right to insist on upholding standards: Badly made life-saving drugs can create life-threatening resistance.

It throws down the gauntlet to the Global Fund, the European Union, the Clinton Foundation and all the agencies and countries using the WHO's "pre-qualification" list of medicines, which are approved for developing countries, but which have not passed the tests demanded in rich countries: The list is designed to encourage local production rather than to save lives.

These donors and governments know about the FDA allegations against Ranbaxy and the long-standing deficiencies of other suppliers, but have not yet altered procurement. The WHO did suspend Ranbaxy anti-retrovirals from its pre-qualification list in 2004, but re-instated them in 2006.

As the contaminated milk horror grows in China, quality control in food and drug manufacturing in the rapidly-developing world is a matter of life and death. India already supplies 75 percent of the world's counterfeit and sub-standard drugs.

U.S. patients have the FDA on their side, but no one is protecting the interests of the poor in developing countries: This scandal must be seized by governments, charities and pressure groups to impose quality control on the WHO's "pre-qualification" list and save patients in Africa and Asia.

Roger Bate is a resident fellow at AEI.

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

Roger
Bate
  • Roger Bate is an economist who researches international health policy, with a particular focus on tropical disease and substandard and counterfeit medicines. He also writes on general development policy in Asia and Africa. He writes regularly for AEI's Health Policy Outlook.
  • Phone: 202-828-6029
    Email: rbate@aei.org
  • Assistant Info

    Name: Katherine Earle
    Phone: (202) 862-5872
    Email: katherine.earle@aei.org

What's new on AEI

image Getting it right: US national security policy and al Qaeda since 2011
image Net neutrality rundown: What the NPRM means for you
image The Schuette decision
image Snatching failure from victory in Afghanistan
AEI on Facebook
Events Calendar
  • 21
    MON
  • 22
    TUE
  • 23
    WED
  • 24
    THU
  • 25
    FRI
Wednesday, April 23, 2014 | 12:00 p.m. – 1:30 p.m.
Graduation day: How dads’ involvement impacts higher education success

Join a diverse group of panelists — including sociologists, education experts, and students — for a discussion of how public policy and culture can help families lay a firmer foundation for their children’s educational success, and of how the effects of paternal involvement vary by socioeconomic background.

Thursday, April 24, 2014 | 12:00 p.m. – 1:30 p.m.
Getting it right: A better strategy to defeat al Qaeda

This event will coincide with the release of a new report by AEI’s Mary Habeck, which analyzes why current national security policy is failing to stop the advancement of al Qaeda and its affiliates and what the US can do to develop a successful strategy to defeat this enemy.

Event Registration is Closed
Friday, April 25, 2014 | 9:15 a.m. – 1:15 p.m.
Obamacare’s rocky start and uncertain future

During this event, experts with many different views on the ACA will offer their predictions for the future.   

Event Registration is Closed
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.